The Telethon Institute of Genetics and Medicine
Quality research to understand the mechanisms behind rare genetic diseases
Discover TigemWelcome to Tigem!
The Telethon Institute of Genetics and Medicine (TIGEM) is a Telethon Foundation organization
The Telethon Institute of Genetics and Medicine (TIGEM) in Naples (Italy) was created in 1994 by the Italian Telethon Foundation
to foster research on genetic diseases.
The mission of Tigem is to elucidate the molecular mechanisms underlying genetic diseases and to develop therapeutic strategies.
The Institute is owned and managed by the Italian Telethon Foundation.
Our Vision
The Tigem has the sole purpose of executing top quality research to understand the mechanisms behind rare genetic diseases, and furthermore, to apply new knowledge to the development of novel treatments.
Research
Description text....lorem ipsum dolor sit nequam note clarum siam.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Read More
MiT/TFE factors control ER ‐phagy via transcriptional regulation of FAM 134B
2020 November, 12short description of the news item...lorem ipsum dolor sit nequam calendam tortus not fuisse giustitiam
Read more
De novo SMARCA2 variants clustered outside the helicase domain cause a new recognizable syndrome with intellectual disability and blepharophimosis distinct from Nicolaides-Baraitser syndrome
2019 March, 7short description of the news item...lorem ipsum dolor sit nequam calendam tortus not fuisse giustitiam
Read more
MiT/TFE factors control ER ‐phagy via transcriptional regulation of FAM 134B
2020 November, 12short description of the news item...lorem ipsum dolor sit nequam calendam tortus not fuisse giustitiam
Read more
De novo SMARCA2 variants clustered outside the helicase domain cause a new recognizable syndrome with intellectual disability and blepharophimosis distinct from Nicolaides-Baraitser syndrome
2019 March, 7short description of the news item...lorem ipsum dolor sit nequam calendam tortus not fuisse giustitiam
Read morePhD Programs
TIGEM collaborates with three leading universities to offer three PhD programs.
Successful completion of either program leads to conferral of a British or Italian PhD degree, depending on the awarding institution of the chosen program.
We had the pleasure to host Mirko Cortese from @UniHeidelberg for our #TigemOnlineSeminar
— Tigem Telethon (@Tigem_Telethon) January 13, 2021
He showed us an integrative analysis of #SARSCoV2 -induced cellular remodeling. pic.twitter.com/etbXO8TQK4
Congratulations to Gerarda Cappuccio from Brunetti’s lab for her publication on the #AJMG @WileyGenetics. She and others published a work on a pilot clinical trial with #losartan in #Myhre syndrome #TigemScience
— Tigem Telethon (@Tigem_Telethon) January 8, 2021
Read more here 👇https://t.co/WRNncvVwQx pic.twitter.com/Uytyw4XYvS
Congratulations to Leandro Soria from Brunetti’s lab for his recent publication on @EmboMolMed. He discovered that #beclin1 ‐mediated activation of autophagy improves proximal and distal urea cycle disorders. Read more here 👇 https://t.co/e8aV3iiTpJ #TigemScience pic.twitter.com/V5i8VDDej0
— Tigem Telethon (@Tigem_Telethon) January 6, 2021
